Previous 10 | Next 10 |
VANCOUVER, Wash. and NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtu...
VANCOUVER, Wash. and NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced two senior executive hires in newly cre...
Absci ( NASDAQ: ABSI ) said it signed a collaboration agreement with an undisclosed biotech company. Absci noted that the partner is a stealth-mode company, led by biotech industry executives, focused on developing antibody-drug-conjugates (ADCs) initially for cancer i...
VANCOUVER, Wash. and NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a collaboratio...
AC Immune (ACIU) -32% as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx (ACLX) -10% on upsizing of follow-on public offering of 7M shares at $...
Absci press release (NASDAQ:ABSI): Q1 GAAP EPS of -$0.33 misses by $0.04. Revenue of $0.82M (-22.6% Y/Y) misses by $1.04M. Cash and cash equivalents as of March 31, 2022 was $226.0 million, as compared to $252.6 million as of December 31, 2021, representing sufficient cash and cash equiv...
VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended ...
VANCOUVER, Wash., April 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the upcoming B...
Absci (NASDAQ:ABSI) said it has opened its Absci AI Research Lab in Manhattan's Plaza District to expand drug discovery capabilities. The lab will help expand Absci's Denovium Engine AI platform and deployment of its machine learning pipeline for predicting therapeutic protein ...
VANCOUVER, Wash. and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of the Absci AI Research L...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday,...
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stoc...
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 3 rd Annual Life Sciences AI Summit on June 26-27 in New York, ...